Oculis Holding
Swiss/Icelandic ophthalmology biotech listed on Nasdaq. Oculis is developing a focused pipeline of topical and neuroprotective candidates for major ophthalmic markets: diabetic macular oedema, dry eye disease, retinal neuroprotection.
Investment thesis
- 01
Focused ophthalmology pipeline across three distinct assets covering diabetic macular oedema (OCS-01), severe dry eye disease (OCS-02) and retinal neuroprotection (OCS-05).
- 02
OCS-01: optimised topical dexamethasone potentially replacing or delaying intravitreal injections, with a differentiated patient-friendly profile.
- 03
OCS-02 (licaminlimab): topical anti-TNFα antibody, a novel class in severe dry eye where the therapeutic arsenal remains limited.
- 04
OCS-05: small molecule neuroprotective candidate with extension potential beyond ophthalmology.
- 05
Cash position consolidated through post-listing financings, providing visibility through key readouts.
- 06
Experienced team from European ophthalmology development, with strong academic partnerships.
Catalysts
OCS-01: Phase 3 progression in DME
Pivotal trial readouts will condition the regulatory trajectory and the value of the lead asset.
OCS-02 (licaminlimab) — clinical steps in dry eye
Differentiated demonstration versus existing therapies (Restasis, Xiidra, Tyrvaya): the market remains hungry for new options.
OCS-05 — neuroprotection progression
A longer-term programme but potentially structuring if neuroprotection shows a robust signal.
Quarterly financial communications
Tracking of cash consumption and operational execution quality.
Risks
Binary clinical risk
A clinical-stage biotech remains exposed to trial results that can quickly invalidate a thesis, especially in Phase 3.
Competitive landscape in ophthalmology
Ophthalmology is a competitive sector (AbbVie, Regeneron, Bayer, Novartis, Roche, Santen): commercial positioning to be demonstrated.
Cash and potential dilution
Like any pre-revenue biotech, Oculis may need to strengthen its balance sheet: to monitor in the next 18-24 months.
Nasdaq volatility and float
Nasdaq listing with limited float: price moves can be amplified by technical flows.
Calendar
- 2026Quarterly resultsEarnings
- 2026Annual general meetingAGM
- 2026Pipeline clinical readoutsClinical
Governance
International leadership from European ophthalmology industry. Mixed board (Switzerland, United States). Capcordia documents AGM resolutions, votes and financial communications in French for francophone shareholders.
This file is editorial and does not constitute investment advice. Individual shareholders are responsible for their own decisions.